Results 91 to 100 of about 5,304 (170)

Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia.

open access: yes, 2021
Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). The efficacy and safety of acalabrutinib monotherapy was evaluated in a treatment-naïve CLL cohort of a single-arm phase 1/2 clinical trial ...
Jain, Nitin   +16 more
core  

Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)—an analysis of an administrative health claims database

open access: yesCardio-Oncology
Background First generation Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib have been associated with cardiovascular toxicities. Newer generation BTKi (e.g.,acalabrutinib and zanabrutinib) have been associated with lower incidence of ...
Srilakshmi Vallabhaneni   +5 more
doaj   +1 more source

Frontline Fixed-Duration Acalabrutinib Plus Venetoclax in Rapidly Progressive _IGHV_-Mutated CLL: A Case Report

open access: yeshealthbook TIMES. Oncology Hematology
# Introduction The phase III AMPLIFY trial established fixed-duration acalabrutinib plus venetoclax as an effective, all-oral, chemotherapy-free frontline therapy for chronic lymphocytic leukemia (CLL).
Young-Lan Song, Adrian Schmidt
doaj   +1 more source

Acalabrutinib: First Global Approval

open access: yes, 2018
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Anthony Markham is a contracted employee of Adis/Springer, is responsible for the article contentand declares no ...
Anthony Markham (4891627)   +1 more
core   +1 more source

Central nervous system posttransplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation successfully treated with combination therapy of acalabrutinib and immunochemotherapy: A case report and literature review

open access: yeseJHaem
Here, we report a case of Epstein‐Barr virus‐positive central nervous system‐post‐transplant lymphoproliferative disorder (CNS‐PTLD) patient who failed to achieve complete metabolic remission (CMR) after successively trying a methotrexate‐based regimen ...
Peihao Zheng   +4 more
doaj   +1 more source

Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib – Case report

open access: yeseJHaem
Central nervous system (CNS) involvement by mantle cell lymphoma (MCL) is rare and portends a poor prognosis. We describe the first patient to have a complete response with front‐line treatment with single‐agent acalabrutinib for MCL CNS.
Aisling Barrett   +6 more
doaj   +1 more source

Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

open access: yes, 2020
Background: Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) often have a poor prognosis despite therapies using second-line chemoimmunotherapy. Achievement of CR with second-line therapy is associated with improved long-term
Fesler, Joanna   +16 more
core  

Comparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study. [PDF]

open access: yesCurr Oncol
Awad M   +7 more
europepmc   +1 more source

Acalabrutinib Maleate Tablets: The Physiologically Based Biopharmaceutics Model behind the Drug Product Dissolution Specification

open access: yes
Acalabrutinib maleate tablets correspond to an improved formulation compared to acalabrutinib capsules as they can be dosed with and without acid reducing agents and therefore benefit more cancer patients.
James Mann (4385431)   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy